Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 2Suspended 2Recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Breast 1

Conditions

Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 9Vincristine 6Specimen Handling 6Prednisone 6Rituximab 5Doxorubicin 5Magnetic Resonance Spectroscopy 4zanubrutinib 3prednylidene 3fludarabine 3deltacortene 3Biopsy 3tazemetostat 2fludarabine phosphate 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1brincidofovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Antibodies, Monoclonal × Lymphoid × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00077493 2007-12-28

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

MedImmune LLC

Phase 1 Suspended
95 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡